In this article
- What is KPV?
- How does KPV work?
- KPV peptide benefits: claims versus evidence
- KPV for gut and IBD research
- KPV vs BPC-157 for gut research
- KPV oral vs injection: capsules or subcutaneous?
- KPV dosage: ranges reported in research
- Storage and handling
- KPV side effects
- Why KPV appears in blends
- Frequently asked questions
- References
Most of what is said about KPV peptide benefits traces back to laboratory work on gut inflammation. In cell cultures and mice, this very short peptide dampened inflammatory signalling and eased experimental colitis. Nobody has yet published a controlled human trial of KPV by injection or by mouth, and no regulator has approved it.
- KPV is the final three residues of alpha-MSH, and it appears to act largely without engaging melanocortin receptors.
- Its best-known support is a pair of 2008 animal and cell papers on intestinal inflammation.
- Skin, wound and “immune support” claims are mostly inferred from related biology or simply untested.
- Safety, benefit and dose in people remain unestablished.
What is KPV?
KPV (lysine-proline-valine, also written alpha-MSH 11-13) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone. Researchers noticed that this small piece keeps the parent hormone’s anti-inflammatory activity but lacks the pigmentation and appetite effects associated with the full hormone or with compounds such as melanotan 2. Further detail is on the KPV research profile and the Signal IQ KPV page.
How does KPV work?
Unlike the whole hormone, KPV seems to reduce inflammation mostly independently of melanocortin receptor binding. Studies have concentrated on its ability to inhibit NF-kB, a central pathway controlling inflammatory gene expression, and to adjust cytokine production in gut and skin models. It is characterised as tuning excessive inflammatory signalling rather than switching the immune system off broadly.
KPV peptide benefits: claims versus evidence
| Claim | Where the evidence stands |
|---|---|
| Eases colitis and IBD-type inflammation | Animal and cell experiments |
| Is taken up by intestinal cells | Cell and mouse data point to the PepT1 transporter |
| Helps psoriasis or irritated skin | Largely inferred from alpha-MSH biology; sparse direct data |
| Speeds wound repair or boosts immunity | Marketing assertions without human trials |
| Improves gut health in healthy people | Never studied |
KPV for gut and IBD research
The intestine is where research interest is strongest. Two papers carry most of the weight:
- Dalmasso et al., Gastroenterology, 2008: intestinal cells took up KPV through PepT1; inflammatory signalling dropped and chemically triggered colitis in mice was milder.
- Kannengiesser et al., Inflammatory Bowel Diseases, 2008: inflammation was lower in two separate mouse models of IBD.
Beyond these, investigators have looked at effects on intestinal barrier integrity and on skin-irritation and wound models. Such results are promising starting points, but they do not demonstrate efficacy or safety in people, and they supply no human dose.
KPV vs BPC-157 for gut research
The two are often discussed together because they tackle different problems. KPV is studied for regulating inflammatory signalling; BPC-157 is studied for tissue repair and blood-vessel formation. Signal IQ describes them as complementary in theory, not as a proven combination. Neither has controlled human data for gut disease.
KPV oral vs injection: capsules or subcutaneous?
Vials and capsules contain the same sequence. The vial is a freeze-dried powder for mixing, whereas capsules are made for oral-route research protocols. Laboratory evidence of gut-cell uptake explains the interest in oral forms, yet it was gathered in cells and mice, and no human trial compares the two routes. Which one reaches which tissue in people is unknown.
KPV dosage: ranges reported in research
| Range | Reported amount | Syringe units | Frequency |
|---|---|---|---|
| Standard / lower | 500 mcg | 5 units | Daily, 5 to 7 days per week, subcutaneous |
| Advanced | 1 mg | 10 units | Daily, 5 to 7 days per week, subcutaneous |
The suggested research cycle is 8 to 12 weeks on and about 2 to 4 weeks off. Those unit counts assume a 10 mg vial mixed with 1 mL of bacteriostatic water (10 mg/mL); see how to reconstitute peptides and the peptide dosage chart. These are ranges in research protocols, not recommendations.
Storage and handling
Handling guidance calls for storing and mixing according to the batch’s certificate of analysis, then refrigerating after reconstitution, using sterile technique throughout. General principles are in how to store peptides.
KPV side effects
Side effects in people have not been studied systematically, so no dependable frequencies exist. Since no approved version exists, products are made without regulatory checks on identity, purity or sterility, a hazard in itself. See peptide side effects, are peptides safe and how to read a peptide CoA.
Why KPV appears in blends
Some combination products pair it with GHK-Cu, BPC-157 and TB-500. The reasoning is the anti-inflammatory theory above, not human trials of any blend.
Frequently asked questions
What is KPV peptide?
A three-residue piece (Lys-Pro-Val) of alpha-MSH, investigated for anti-inflammatory activity.
What are the benefits of KPV?
Laboratory and mouse work shows less intestinal inflammation. Human benefit has not been demonstrated in controlled trials.
Is KPV good for gut health or IBD?
That is where research attention lies, but all of the evidence is preclinical.
Is KPV related to melanotan?
Both derive from alpha-MSH, but KPV is the smallest active fragment and lacks the pigmentation activity studied in melanotan analogues.
Is oral KPV as effective as injection?
Untested in people. Cell studies show gut uptake, but no human trial compares routes.
Is KPV approved by the FDA?
No.
References
- Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 2008 — pubmed.ncbi.nlm.nih.gov
- Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis, 2008 — pubmed.ncbi.nlm.nih.gov
Go deeper on Signal IQ
Still have questions? Ask Pulse, Signal IQ’s free AI research assistant, or compare doses in the Peptide Dosage Chart.
Ask PulseEducational content only. Nothing here is medical advice or a recommendation to use any compound. Many peptides discussed are research compounds not approved for human use. Talk to a qualified clinician about your situation. Signal IQ does not sell peptides.



